Nuformix plc announced that the Company is to receive new immediate and near-term undisclosed milestone payments as part of an update to its NXP001 exclusive licensing agreement with Oxilio Ltd. Under the revised agreement with, Oxilio will acquire ownership of Nuformix's NXP001 patent estate, with Nuformix receiving the additional milestone payments referred to above, whilst retaining further development milestones and royalties capped at PS2 million per year.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.185 GBX | 0.00% | 0.00% | -43.08% |
03-01 | Nuformix announces subscription to raise GBP150,000 | AN |
01-15 | Nuformix plc Reports Earnings Results for the Eighteen Months Ended September 30, 2023 | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-43.08% | 1.89M | |
+32.36% | 698B | |
+26.51% | 568B | |
-4.40% | 358B | |
+19.46% | 328B | |
+3.50% | 283B | |
+16.34% | 238B | |
+6.68% | 203B | |
-9.08% | 198B | |
+8.62% | 165B |
- Stock Market
- Equities
- LVRT Stock
- News Nuformix plc
- Nuformix plc Receives New NXP001 Development Milestone Payments in Updated Oxilio Agreement